Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | NEJM
Original Article from The New England Journal of Medicine — Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Related Articles
LIFE IN HEARTS
Issue 02 has inspiring WWLE stories; an article by Dr. Colleen Norris on a very important Canadian initiative for women’s heart health; and Annie takes…
Exposome in ischaemic heart disease: beyond traditional risk factors
Abstract. Ischaemic heart disease represents the leading cause of morbidity and mortality, typically induced by the detrimental effects of risk factors on the c
Personalised Care of Patients with Heart Failure‒ International Survey on Healthcare Professionals’ perception of practice guidelinesGlobal assessment of gaps in heart failure guidelines and their implementationSurvey completion time: 6 mins | Personalised Care of Patients with Heart Failure ‒ Inter
Personalised Care of Patients with Heart Failure ‒ International Survey on Healthcare Professionals’ perception of practice guidelines Global assessment of gaps in heart failure guidelines…
e-SPACE Heart Failure 2023
Register now for the global online conference e-SPACE Heart Failure on TBC October 2023. Experts discuss the latest on heart failure guidelines in clinical practice.
Differences between heart failure specialists and non‐specialists regarding heart failure drug implementation and up‐titration
Click on the article title to read more.
D.E. Systems – Registration | MyConference Suite
In the FireFox address bar, type about:config. Look for the javascript.enabled setting. Set it to true by right-clicking and pressing toggle. On the Tools menu,…
A big STEP for treatment of heart failure with preserved ejection fraction
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in…
